2009 PhRMA Code Revisions: Benchmarking of Leading Pharmaceutical Companies' Approaches and Responses |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
This study benchmarks specific PhRMA
policies at leading pharmaceutical and biotech companies. The
study provides specific policies and tactics implemented, and includes:
Descriptions of the following:
This one-of-a-kind report captures the
responses of over 100 practicing oncologists in the United States – as
they are asked to rate the effectiveness of leading oncology sales
forces in regard to the following attributes:
We not only capture the revealing survey results, but PharmaForce digs deeper by conducting targeted interviews with members of the “best” and “worst” performing sales forces to uncover the reasons for their rankings. This program analyzes in detail the marketing expenditures of leading oncology franchises in the top five countries in Europe (i.e., France, Germany, Italy, Spain and the United Kingdom). The key expenditures benchmarked include:
* Save 5% -- Mention "PharmCast.com" when purchase. To receive more information about the study, please click on the following "Request for Info" link.
|
| [
Outsourcing Guide
] [
Cont. Education
] [
Software/Reports
] [
Training Courses ]
[ Web Seminars ] [ Jobs ] [ Consultants ] [ Buyer's Guide ] [ Advertiser Info ] [ Home ] [ Pharm Patents / Licensing ] [ Pharm News ] [ Federal Register ] [ Pharm Stocks ] [ FDA Links ] [ FDA Warning Letters ] [ FDA Doc/cGMP ] [ Pharm/Biotech Events ] [ Newsletter Subscription ] [ Web Links ] [ Suggestions ] [ Site Map ] |